Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12002MR)

This product GTTS-WQ12002MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12002MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2282MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ15489MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ3924MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ6615MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ3223MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ3578MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ11296MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ15195MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW